Roivant Sciences
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spec...
Latest News
5 days ago · seekingalpha.com
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline MomentumRoivant Sciences Ltd. remains a Buy as its diversified "-vant" model delivers multiple blockbuster pipeline opportunities and robust cash reserves. Immunovant's IMVT-1402 shows superior efficacy in rheumatoid arthritis, but regulatory and translational hurdles remain for broader adoption. Priovant's LISRAYA launches in dermatomyositis, with promising Phase 3 data in non-infectious uveitis, while Pulmovant's mosliciguat demonstrates best-in-class Phase 2 results in PH-ILD.
6 days ago · globenewswire.com
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA DermatologyDURHAM, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced the publication in JAMA Dermatology of results from the Phase 2 portion of the BEACON study, a randomized, double-blind, placebo-controlled trial evaluating oral brepocitinib in adults with cutaneous sarcoidosis (CS). The publication describes improvements in skin disease activity and skin-related quality of life over 16 weeks of treatment, with 69.2% of participants receiving brepocitinib 45 mg once daily achieving “Clear” or “Almost Clear” skin with at least a 2-category improvement, compared with none of the participants receiving placebo (P = 0.0047).
7 days ago · seekingalpha.com
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call TranscriptRoivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 9, 2026 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Yaron Werber - TD Cowen, Research Division Thomas Smith - Leerink Partners LLC, Research Division Yuchen Ding - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Patrick Culliton - Stifel, Nicolaus & Company, Incorporated, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Jacob Goell - Wells Fargo Securities, LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Douglas Tsao - H.C.
8 days ago · marketbeat.com
Roivant Sciences Q2 Earnings Call HighlightsRoivant Sciences NASDAQ: ROIV reported $31 million in net revenue from the initial launch of LISRAYA and said an experimental rheumatoid arthritis treatment met its primary endpoint in a randomized withdrawal study.
8 days ago · zacks.com
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue EstimatesRoivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.41.
26 days ago · seekingalpha.com
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis TranscriptRoivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
27 days ago · marketbeat.com
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis ResultsRoivant Sciences NASDAQ: ROIV reported positive Phase III results from its CLARITY-1 and CLARITY-2 studies evaluating brepocitinib, which the company referred to as Brepo, in noninfectious uveitis (NIU), an inflammatory eye disease that can result in vision loss.
27 days ago · globenewswire.com
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026BASEL, Switzerland and LONDON and NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 9, 2026, to report its financial results for the second quarter ended September 30, 2026, and provide a business update.
2 months ago · marketbeat.com
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 MonthsRoivant Sciences NASDAQ: ROIV CEO Matthew Gline outlined the company's priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant's IMVT-1402, and expansion of its pulmonary hypertension program.
2 months ago · globenewswire.com
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus ErythematosusImmunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced topline results from Period 1 of Immunovant's proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ROIV